Demetrios G Vavvas(@VavvasRetina) 's Twitter Profile Photo

On the 'reduced' need of injections of the newer drugs in neovascular (wet) AMD over one year. Interesting summary of the data from the major studies.
HD VABYSMOⓇ (faricimab-svoa) Regeneron -2

On the 'reduced' need of injections of the newer drugs in neovascular (wet) AMD over one year. Interesting summary of the data from the major studies.
#Faricmab #Vabysmo #EyleaHD #Eylea VABYSMOⓇ (faricimab-svoa) Regeneron #ANG-2 #VEGF #lucentis #ranibizumab #AMD #wetAMD #PULSAR
account_circle
Allocator(@wetamd19028) 's Twitter Profile Photo

$OCUL JEFF: Ph1 DR topline came out as a surprise, and so was the stock reaction (-40% in 2 days). We spoke to a KOL & key points are 1) DR has sig unmet needs & only ~10% pts receive tx due to frequent dosing

account_circle
Allocator(@wetamd19028) 's Twitter Profile Photo

2) it is not a fair comparison to Eylea Ph3 due to small N bias & one dose of AXPAXLI, 3) efficacy trade-off for convenience is acknowledged on 40-50% 2-step DRSS improvement in Ph3. The bottom line is DR is not in OCUL val, and we see sell-off as overdone.

account_circle
Retina Specialist(@RetSpecMag) 's Twitter Profile Photo

In this new issue, find clinical pearls on pediatric retinal detachment, a guide for suprachoroidal injections, an update on gene therapy for Stargardt & more.

Find it all in the Nov/Dec issue or at Retina-Specialist.com 📖
specialist

In this new issue, find clinical pearls on pediatric retinal detachment, a guide for suprachoroidal injections, an update on gene therapy for Stargardt & more.

Find it all in the Nov/Dec issue or at Retina-Specialist.com 📖
#retina #retinaspecialist #ophthalmology #AMD #wetAMD
account_circle
Ashvattha Therapeutics(@AshvatthaTx) 's Twitter Profile Photo

As 2023 ends, we reflect on our year of firsts.

✅ 1st patient dosed in the Phase 2 study of our for and .

✅ 1st patient enrolled in the Phase 1 study of our imaging agent in and healthy volunteers.

We look forward to sharing data in 2024!

As 2023 ends, we reflect on our year of firsts.

✅ 1st patient dosed in the Phase 2 study of our #nanomedicine for #WetAMD and #DME.

✅ 1st patient enrolled in the Phase 1 study of our imaging agent in #ALS and healthy volunteers.

We look forward to sharing data in 2024!
account_circle
Clearside Biomedical, Inc.(@clearsidebio) 's Twitter Profile Photo

We are excited to be featured in the newest edition of *Retinal Physician* looking at potential innovations in treatment in .

account_circle
Retina Specialist(@RetSpecMag) 's Twitter Profile Photo

Calling out retina’s ‘head-in-the-sand’ approach to mental health and neovascular AMD
An urgent need exists to raise awareness among retina specialists about the mental health crisis among patients with AMD.
retina-specialist.com/article/callin…
specialist

Calling out retina’s ‘head-in-the-sand’ approach to mental health and neovascular AMD
An urgent need exists to raise awareness among retina specialists about the mental health crisis among patients with AMD. 
retina-specialist.com/article/callin…
#retina #retinaspecialist #AMD #wetAMD
account_circle